Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial.

Priya Vart,Niels Jongs,David C Wheeler,Hiddo J L Heerspink,Anna Maria Langkilde,Glenn M Chertow

JAMA network open（2023）

引用 2|浏览20

暂无评分

摘要

This secondary analysis of a randomized clinical trial investigates the relative effectiveness and safety of the sodium-glucose cotransporter-2 inhibitor dapagliflozin for Black vs White patients with chronic kidney disease (CKD) in North and South America.

查看译文

关键词

dapagliflozin,chronic kidney disease,kidney disease,white patients

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要